Either somatic "second hit" mutations predicted to truncate the protein or loss of heterozygosity at the BHD syndrome locus was identified in 70% of renal tumors from BHD patients [12] supporting a tumor suppressor function for FLCN. This evidence concerns the gene FLCN and neoplasm.